See more : GuiZhou SanLi Pharmaceutical Co.,Ltd (603439.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Rallybio Corporation (RLYB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rallybio Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
- Concord Securities Co., Ltd. (6016.TWO) Income Statement Analysis – Financial Results
- Phoenix Spree Deutschland Limited (PSDL.L) Income Statement Analysis – Financial Results
- HOTLAND Co.,Ltd. (3196.T) Income Statement Analysis – Financial Results
- Independence Gold Corp. (IEGCF) Income Statement Analysis – Financial Results
- Corsair Partnering Corporation (CORS) Income Statement Analysis – Financial Results
Rallybio Corporation (RLYB)
About Rallybio Corporation
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 150.00K | 167.00K | 109.00K | 62.03K | 26.34K |
| Gross Profit | -150.00K | -167.00K | -109.00K | -62.03K | -26.34K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 53.54M | 40.69M | 26.91M | 17.63M | 11.37M |
| General & Administrative | 25.39M | 27.20M | 18.74M | 7.67M | 6.28M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 25.39M | 27.20M | 18.74M | 7.67M | 6.28M |
| Other Expenses | 0.00 | 342.00K | 96.00K | 241.00K | 24.00K |
| Operating Expenses | 78.93M | 67.88M | 45.65M | 25.30M | 17.64M |
| Cost & Expenses | 78.93M | 67.88M | 45.65M | 25.30M | 17.64M |
| Interest Income | 6.15M | 1.96M | 54.00K | 171.00K | 197.00K |
| Interest Expense | 0.00 | 0.00 | 10.00K | 49.00K | 39.00K |
| Depreciation & Amortization | 150.00K | 167.00K | 109.00K | 62.03K | 26.34K |
| EBITDA | -72.37M | -65.41M | -45.39M | -24.83M | -17.39M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -78.93M | -67.88M | -45.65M | -25.30M | -17.64M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.37M | 2.31M | 140.00K | 363.00K | 182.00K |
| Income Before Tax | -74.56M | -65.58M | -45.51M | -24.94M | -17.46M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -2.04M | 908.00K | 1.50M | -15.00K | 166.00K |
| Net Income | -74.56M | -66.49M | -47.01M | -24.93M | -17.63M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.84 | -2.09 | -1.46 | -0.78 | -0.55 |
| EPS Diluted | -1.84 | -2.09 | -1.46 | -0.78 | -0.55 |
| Weighted Avg Shares Out | 40.45M | 31.82M | 32.13M | 32.13M | 32.13M |
| Weighted Avg Shares Out (Dil) | 40.45M | 31.82M | 32.13M | 32.13M | 32.13M |
Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025
Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women
Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference
Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting
Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis
National Vision Releases 2023 Sustainability Report
Rallybio to Present at Upcoming Investor Conferences
Rallybio (RLYB) Upgraded to Buy: What Does It Mean for the Stock?
Source: https://incomestatements.info
Category: Stock Reports